TABLE 1.
Demographics and baseline characteristics of patients infected with SARS‐CoV‐2 or influenza A virus
| SARS‐CoV‐2 (n = 41) | Influenza A (n = 37) | P‐value | |
|---|---|---|---|
| Characteristics | |||
| Age, years | 46 (39‐50) | 55 (45‐67) | <.01 |
| Sex | .40 | ||
| Men | 15 (36.6%) | 17 (45.9%) | |
| Women | 26 (63.4%) | 20 (54.1%) | |
| Signs and symptoms | |||
| Fever | 32 (78.0%) | 28 (75.7%) | .80 |
| Highest temperature, °C | .70 | ||
| <37.3 | 9 (22.0%) | 9 (24.3%) | |
| 37.3‐38.0 | 15 (36.6%) | 11 (29.7%) | |
| 38.1‐39.0 | 11 (26.8%) | 8 (21.6%) | |
| >39.0 | 6 (14.6%) | 9 (24.3%) | |
| Cough | 22 (53.7%) | 31 (83.8%) | <.01 |
| Myalgia or fatigue | 11 (26.8%) | 8 (21.6%) | .61 |
| Headache | 2 (4.9%) | 2 (5.4%) | .92 |
| Hemoptysis | 1 (2.4%) | 3 (8.1%) | .34 |
| Diarrhea | 2 (4.9%) | 0 (0.0%) | .50 |
| Dyspnea | 1 (2.5%) | 15 (40.5%) | <.01 |
| Respiratory rate > 24 breaths per min | 1 (2.5%) | 4 (10.8%) | .19 |
| Laboratory data | |||
| White blood cell count, ×109/L | .02 | ||
| <4 | 13 (32.50%) | 10 (27.03%) | |
| 4‐10 | 26 (65.00%) | 18 (48.65%) | |
| >10 | 1 (2.50%) | 9 (24.32%) | |
| Lymphocyte count, ×109/L | |||
| <1.0 | 5 (12.50%) | 1 (2.70%) | .20 |
| ≥1.0 | 35 (87.50%) | 36 (97.30%) | |
| Aspartate aminotransferase, U/L | .05 | ||
| ≤40 | 31 (81.58%) | 22 (59.46%) | |
| >40 | 7 (18.42%) | 15 (40.54%) | |
| Total bilirubin, mmol/L | 10.2 (7.1‐15.0) | 8.0 (6.0‐12.0) | .07 |
| Lactate dehydrogenase, U/L | .40 | ||
| ≤245 | 20 (62.50%) | 10 (47.62%) | |
| >245 | 12 (37.50%) | 11 (52.38%) | |
Note. Continuous variables are presented as median (IQR), n (%); categorical variables are presented as number (%). P values tested by one‐way ANOVA for normally distributed variables, Kruskal‐Wallis rank test for not normally distributed continuous variables, and Fisher's exact test for categorical variables, respectively.